Howmet Aerospace enters the final session of September with two stories running in opposite directions: options traders just pushed defensive positioning to a fresh 52-week extreme, while the stock itself is trading nearly $80 below the average analyst price target.
The options angle has deepened since last week's note. The put/call ratio reached 1.6442 on September 29, a new 52-week high, eclipsing the 1.62 reading flagged just one week ago. That puts the PCR at 1.65 standard deviations above its 20-day mean of 1.42, the most skewed toward downside protection since the rolling window began. The shift has been persistent and not brief: through mid-August the PCR was running well below 1.0. It then climbed steadily through September, and the pace has not let up. Options traders are paying for puts at a rate without precedent in the past year, even as the stock recovered 2.5% on the week to close at $230.94.
Short interest is a secondary note, not the main story. Bears have added roughly 40% to their position over the past month, lifting SI to 2.4% of the free float, still a low absolute level. The week-on-week build of 8.4% is worth tracking, but at 9.7 million shares short, this falls far short of any crowded threshold. Borrow remains almost frictionless: cost to borrow is 0.44% and availability is essentially unconstrained, with hundreds of millions of shares still available to lend. The lending market offers no sign of squeeze pressure, and the short score of 34 sits exactly at the 50th percentile of the ORTEX universe.
The Street remains firmly bullish in aggregate, but a crack appeared this week. Wells Fargo's David Strauss cut his price target from $315 to $255 on September 30 while keeping an Equal-Weight rating, the most recent and most bearish single action in the dataset. That move stands against a broader backdrop of constructive analyst activity: Guggenheim initiated at Buy with a $350 target on September 15, and a cluster of firms including JPMorgan, RBC Capital, and BTIG all lifted targets following the August earnings report. The consensus mean target is $334, implying roughly 45% upside from current levels. Valuation multiples tell a different story. The trailing PE is 37.4x and the price-to-book sits at nearly 13x. Both have compressed by about 3 to 8% over the past 30 days as the stock pulled back 12.8% in September, though both remain elevated. The EV/EBITDA of 25.9x has barely moved on the month, holding the stock in premium territory. The analyst recommendation differential factor scores in the 98th percentile of the ORTEX universe, reflecting an unusually lopsided buy consensus, but the EV/EBIT factor scores in just the 14th percentile, flagging stretched valuation by that measure.
The last earnings print is recent context worth noting. When Howmet reported on August 6, the stock fell 3.3% that day and drifted a further half-point lower over the subsequent week. That reaction came despite what was apparently a solid enough quarter to prompt a round of target upgrades. The next print is scheduled for November 6, now 37 days away, and the pattern of options traders building put exposure well ahead of results is consistent with what happened in the weeks before that August report.
The key question for the next few weeks is whether the defensive options positioning reflects a specific concern about the November print, sector-wide caution on aerospace valuations, or simply the drag from a stock that has given back 12% in a single month while the Street's targets have barely moved. The divergence between where analysts think the stock belongs and where it is trading, roughly $100 apart, is now the most visible tension in the setup.
See the live data behind this article on ORTEX.
Open HWM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
